{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:43:13Z","timestamp":1785714193495,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T00:00:00Z","timestamp":1524528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health and Labor Sciences Research Grant","award":["MHLW KAKENHI H26-Kakushintekigan-Ippan-133"],"award-info":[{"award-number":["MHLW KAKENHI H26-Kakushintekigan-Ippan-133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00277-018-3323-8","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T15:23:30Z","timestamp":1524583410000},"page":"1535-1545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-4015","authenticated-orcid":false,"given":"Yoshihiro","family":"Hatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiwa","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikamasa","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Yujiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Monma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,24]]},"reference":[{"key":"3323_CR1","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","volume":"98","author":"S Chiaretti","year":"2013","unstructured":"Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foa R (2013) Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica 98:1702\u20131710","journal-title":"Haematologica"},{"key":"3323_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F, GIMEMA Group (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99:863\u2013871","journal-title":"Blood"},{"key":"3323_CR3","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","volume":"99","author":"B Gleissner","year":"2002","unstructured":"Gleissner B, G\u00f6kbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E, German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536\u20131543","journal-title":"Blood"},{"key":"3323_CR4","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","volume":"104","author":"M Towatari","year":"2004","unstructured":"Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104:3507\u20133512","journal-title":"Blood"},{"key":"3323_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460\u2013466","journal-title":"J Clin Oncol"},{"key":"3323_CR6","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396\u20134407","journal-title":"Blood"},{"key":"3323_CR7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","volume":"19","author":"KH Lee","year":"2005","unstructured":"Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, Kim WK, Lee JS, Seo EJ, Jang S, Park CJ, Chi HS (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19:1509\u20131516","journal-title":"Leukemia"},{"key":"3323_CR8","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornh\u00e4user M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Br\u00fcck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108:1469\u20131477","journal-title":"Blood"},{"key":"3323_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/bmt.2008.296","volume":"43","author":"MJ Burke","year":"2009","unstructured":"Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR (2009) Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant 43:107\u2013113","journal-title":"Bone Marrow Transplant"},{"key":"3323_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","volume":"19","author":"A Tanguy-Schmidt","year":"2013","unstructured":"Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, R\u00e9a D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H, Thomas X (2013) Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant 19:150\u2013155","journal-title":"Biol Blood Marrow Transplant"},{"key":"3323_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3324\/haematol.2014.116954","volume":"100","author":"E Brissot","year":"2015","unstructured":"Brissot E, Labopin M, Beckers MM, Socie G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kroger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gurman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M (2015) Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 100:392\u2013399","journal-title":"Haematologica"},{"key":"3323_CR12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","volume":"16","author":"J Takeuchi","year":"2002","unstructured":"Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R (2002) Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 16:1259\u20131266","journal-title":"Leukemia"},{"key":"3323_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12185-010-0672-z","volume":"92","author":"I Jinnai","year":"2010","unstructured":"Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R (2010) Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. Int J Hematol 92:490\u2013502","journal-title":"Int J Hematol"},{"key":"3323_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"3323_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695\u2013706","journal-title":"Stat Med"},{"key":"3323_CR16","first-page":"43","volume":"33","author":"J Casta\u00f1eda","year":"2010","unstructured":"Casta\u00f1eda J, Gerritse B (2010) Appraisal of several methods to model time to multiple events per subject: modelling time to hospitalizations and death. Rev Colomb Estad 33:43\u201361","journal-title":"Rev Colomb Estad"},{"key":"3323_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/leu.2010.228","volume":"25","author":"S Mizuta","year":"2011","unstructured":"Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R (2011) Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 25:41\u201347","journal-title":"Leukemia"},{"key":"3323_CR18","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1038\/bcj.2012.18","volume":"2","author":"S Mizuta","year":"2012","unstructured":"Mizuta S, Matsuo K, Maeda T, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Takada S, Yokota A, Takatsuka Y, Tamaki S, Imai K, Moriuchi Y, Miyazaki Y, Ohtake S, Ohnishi K, Naoe T (2012) Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J 2:e72","journal-title":"Blood Cancer J"},{"key":"3323_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0925-5710(98)00084-X","volume":"68","author":"M Tanimoto","year":"2008","unstructured":"Tanimoto M, Miyawaki S, Ino T et al (2008) Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 68:421\u2013429","journal-title":"Int J Hematol"},{"key":"3323_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0925-5710(98)00075-9","volume":"68","author":"T Ueda","year":"1998","unstructured":"Ueda T, Miyawaki S, Asou N et al (1998) Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 68:279\u2013289","journal-title":"Int J Hematol"},{"key":"3323_CR21","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"15","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F et al (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 15:4075\u20134086","journal-title":"J Clin Oncol"},{"key":"3323_CR22","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85:2025\u20132037","journal-title":"Blood"},{"key":"3323_CR23","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","volume":"123","author":"S Mizuta","year":"2014","unstructured":"Mizuta S, Matsuo K, Nishiwaki S, Imai K, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Miyamura K, Takahashi S, Onizuka M, Atsuta Y, Suzuki R, Morishima Y, Kato K, Sakamaki H, Tanaka J (2014) Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood 123:2325\u20132332","journal-title":"Blood"},{"key":"3323_CR24","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan R, Rossi G, Pogliani EM, di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A (2010) Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group Protocol 09\/00. J Clin Oncol 28:3644\u20133652","journal-title":"J Clin Oncol"},{"key":"3323_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH (2014) UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123:843\u2013850","journal-title":"Blood"},{"key":"3323_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ajh.24137","volume":"90","author":"SN Lim","year":"2015","unstructured":"Lim SN, Joo YD, Lee KH, Kim DY, Lee JH, Lee JH, Chi HS, Yun SC, Lee WS, Lee SM, Park S, Kim I, Sohn SK, Moon JH, Ryoo HM, Bae SH, Hyun MS, Kim MK, Kim HJ, Yang DH, Eom HS, Lee GW, Jung CW, Won JH, Kim H, Lee JH, Shin HJ, Jang DY (2015) Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 90:1013\u20131020","journal-title":"Am J Hematol"},{"key":"3323_CR27","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lheritier V, Chevret S, Ifrah N, Dombret H, for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125:3711\u20133719","journal-title":"Blood"},{"key":"3323_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2014.118588","volume":"100","author":"N Daver","year":"2015","unstructured":"Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O\u2019Brien S (2015) Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100:653\u2013661","journal-title":"Haematologica"},{"key":"3323_CR29","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lh\u00e9ritier V et al (2006) Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20:1526\u20131532","journal-title":"Leukemia"},{"key":"3323_CR30","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, D\u00fchrsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D, for the GMALL Study Group (2007) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 109:2068\u20132076","journal-title":"Cancer"},{"key":"3323_CR31","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Fo\u00e0 R, Baccarani M, Mandelli F (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676\u20133678","journal-title":"Blood"},{"key":"3323_CR32","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM (2015) Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121:4158\u20134164","journal-title":"Cancer"},{"key":"3323_CR33","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan A, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia confirms superiority of allogeneic transplant over chemotherapy in the pre-imatinib era: results from the international ALL trial MRC UKALLXII\/ECOG2993. Blood 113:4489\u20134496","journal-title":"Blood"},{"key":"3323_CR34","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charrin C, Boucheix C, Lh\u00e9ritier V, Esp\u00e9rou H, MacIntyre E, Vernant JP, Fi\u00e8re D, Groupe d'Etude et de Traitement de la Leuc\u00e9mie Aigu\u00eb Lymphoblastique de l'Adulte (GET-LALA Group) (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood 100:2357\u20132366","journal-title":"Blood"},{"key":"3323_CR35","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2012.164","volume":"26","author":"S Lee","year":"2012","unstructured":"Lee S, Kim DW, Cho BS, Yoon JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Chung NG, Kim HJ, Min CK, Lee JW, Min WS, Park CW (2012) Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 26:2367\u20132374","journal-title":"Leukemia"},{"key":"3323_CR36","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999\u20132007","journal-title":"Blood"},{"key":"3323_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3324\/haematol.2013.085811","volume":"99","author":"M Wetzler","year":"2014","unstructured":"Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA (2014) Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 99:111\u2013115","journal-title":"Haematologica"},{"key":"3323_CR38","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cncr.23666","volume":"113","author":"D Jones","year":"2008","unstructured":"Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM (2008) Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113:985\u2013994","journal-title":"Cancer"},{"key":"3323_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/10428194.2017.1326596","volume":"59","author":"C Motll\u00f3","year":"2018","unstructured":"Motll\u00f3 C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, Gonz\u00e1lez-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hern\u00e1ndez-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, Garc\u00eda-Belmonte D, Gu\u00e0rdia R, Grau J, Feliu E, on behalf of the PETHEMA Group, Spanish Society of Hematology (2018) Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leuk Lymphoma 59:146\u2013154","journal-title":"Leuk Lymphoma"},{"key":"3323_CR40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdw123","volume":"27","author":"JH Yoon","year":"2016","unstructured":"Yoon JH, Yhum HY, Kwak JY et al (2016) Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromsome-positive acute lymphoblastic leukemia. Ann Oncol 27:1081\u20131088","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3323-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T20:38:10Z","timestamp":1571258290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,24]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3323-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,24]]},"assertion":[{"value":"26 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols were approved by JALSG and subsequently reviewed by the institutional review board of each participating center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YH received honoraria from Novartis, Kyowa-Hakko Kirin, and Chugai Pharmaceutical. YT received honoraria from Novartis. YM received honoraria and research funding from Novartis. TN received research funding or patents and royalties from Astellas Pharma, Celgene, Kyowa-Hakko Kirin, Nippon Boehringer Ingelheim, Otsuka Pharmaceutical, Pfizer, Toyama Chemical, and Chugai Pharmaceutical. Imatinib was provided by Novartis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}